Dr Sreejith Raveendran

Dr Sreejith Raveendran is an Assistant Professor/ Senior Lecturer in Biotechnology at the School of

Health and Life Sciences, Teesside University, UK. Dr Sree leverages advanced bio-nanotechnological

platforms to create novel nanotherapeutics targeting cancers, explicitly focusing on endocrine-related

cancers and glioblastoma (brain tumours). His groundbreaking research involves synthesising and

characterising novel nano vectors equipped with multifunctional moieties, chemotherapeutic agents, and

imaging modalities. These sophisticated nano vectors are designed for precision-targeted delivery of drugs,

genes, and proteins, enhancing the efficacy and specificity of cancer treatments. His expertise in developing

multifunctional nanoparticles allows for simultaneous therapeutic and diagnostic applications, facilitating

early detection and effective treatment of aggressive cancers. By integrating chemotherapeutic agents with

targeted nano vectors, Dr Sree aims to minimise side effects and maximise therapeutic outcomes, offering

hope for more effective and personalised cancer therapies.

Dr. Sree is an expert in biomedical science, having spent 17 years in research and teaching.

Academic and industrial domains are included. He completed his PhD in Bionanoscience fusion under the

prestigious MEXT fellowship from Japan. Then, he conducted several years of intensive research in cancer

nanotechnology at the Bio-Nano Electronics Research Centre, Toyo University, Japan. Later, he relocated

to the University of Brighton, UK, after receiving the highly competitive Marie Sklodowska Curie Actions

Individual Fellowship (European Commission) for research on Brain Cancer. In his early career, he worked as

a Research Associate in Infection Pharmacology at AstraZeneca India Pvt. Ltd. for drug discovery research

against tuberculosis. He served as a Junior Research Associate in the Bio-resources division of Abl

Biotechnologies Ltd., India, for extraction and biopharmaceutical applications of marine products and

secondary metabolites. Before coming to Teesside, Dr. Sree was a Project Coordinator for the India-Japan

Bio Nano Mission Phase-II project for the Indian Institute of Technology, Delhi (IITD)'s Collaborative research

and education program. He has been networking and mentoring postdoctoral and doctoral researchers, as

well as senior researchers, to encourage them to pursue cutting-edge research in the fields of targeted

theranostics and nanobiotechnology. His prime areas of research include but are not limited to personalised

medicine, nanomolecular targeting, biosensor development and novel therapeutics for cancers. He received

several awards, including the IAAM Young Scientist Award in 2018, the Nanosmat Prize in 2014 and much

extramural funding, including two prestigious global grants. He has published 23 research papers, 2 review

papers, and 3 book chapters and has presented 25+ international conferences, symposiums, and invited

talks. Dr Sree is a member of the International Research Advisory Board at IQRAA Hospital and Research

Centre India. He is an editor for various special issues in the Scientific Journals, viz Pharmaceutics, Processes

and Cancer. Dr Sree has established an outstanding international research network with premier research

institutes, industries, and universities in the US, UK, India, Europe, Japan, Singapore, and Australia.

Dr Sree’s primary scientific goal is to develop a therapeutic cancer nanovaccine and a wearable

nanosensor using advanced nanotechnology and Artificial Intelligence tools for early- cancer diagnosis,

treatment, and sustainable wellness.